Trial Profile
Clinical Trials Insight: 700053114
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2010
Price :
$35
*
At a glance
- Drugs Ropeginterferon alfa-2b (Primary)
- Indications Hepatitis B; Hepatitis C
- Focus Adverse reactions
- Sponsors PharmaEssentia Corporation
- 02 Feb 2010 New trial record.